Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03560479
Other study ID # HP002-001
Secondary ID 2016-004269-14
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 21, 2018
Est. completion date December 2023

Study information

Verified date August 2020
Source Hamlet Pharma AB
Contact Catharina Svanborg, Prof.
Phone +4640122505
Email catharina.svanborg@med.lu.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the tolerability and preliminary anti-tumour effect of alpha1H in adults with non-muscle invasive bladder cancer, who are awaiting transurethral surgery.

In the main, blinded part of the study, one group of subjects will receive treatment with alpha1H and the other half will receive placebo. In a second, dose-escalation part of the study, a third and fourth group of subjects will receive increased doses of alpha1H.

The treatment is given on 6 occasions during a period of 22 days. The study duration is 8 - 12 weeks including scheduled follow-up and up to 27 months when an optional 24-months non-interventional follow-up period is included.


Description:

Protein-lipid complexes represent a new type of tumouricidal biologicals, with broad effects against cancers of different origins. The investigational product alpha1H is a synthetic peptide, corresponding to the alpha1 domain of α-lactalbumin, in complex with oleic acid. Alpha1H is a further development product of HAMLET, a complex between human alpha-lactalbumin and oleic acid, which has shown broad anti-tumor activity with a high degree of selectivity.

This study is a combined phase 1/2, placebo controlled, double blind study in subjects with non-muscle invasive bladder cancer awaiting transurethral resection of bladder (TURB). The first, main part of the study is randomized 1/1 and the subjects will receive intravesical instillation of either alpha1H or placebo on 6 occasions during a period of 22 days (on days 1, 3, 5, 8, 15 and 22). In a second, open, dose-escalation (DE) part of the study, two additional groups will receive increased doses of alpha1H in a standard 3+3 design in order to determine a Maximum Tolerated Dose (MTD) or alternatively, a Maximum Administered Dose (MAD). The same treatment schedule as in part 1 will be followed. One group will receive a dose of 5 times the original dose and, if tolerated, the last group will receive a dose of 10 times the original dose.

Cell shedding is quantified and characterized at each treatment occasion. The bladder tumors are characterized prior treatment and prior to the scheduled surgery. Remaining tumors will be removed by TURB (according to European Association of Urology (EAU) Guidelines recommendations) and tissues will be obtained for analyses.

A follow-up Visit will take place 30 days after the last administration of study treatment.

The total study duration of the main study is 8 - 12 weeks. After the main study, the subjects may continue in an optional extended 24-months follow-up period.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date December 2023
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient with non-muscle invasive papillary bladder cancer (NMIBC) based on cystoscopy appearance, on the waiting list for TURB.

- Negative pregnancy test in women of childbearing potential.

- Appropriate methods of contraception in women of childbearing potential during study.

- Patients should be able to keep the content of the bladder for at least one hour.

Exclusion Criteria:

- Patient with a previous history of muscle invasive bladder cancer.

- Patient with a history of NMIBC with an interval shorter than 6 months after previous TURB.

- Previous intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in the last 12 months.

- Previous intravesical chemotherapy in the last 12 months.

- Participants with any other cancer diagnosis within the last 5 years (except of skin basaliomas).

- Acute urinary tract infection

- Participants with prior radiotherapy or systemic chemotherapy.

- Participants receiving any other investigational agent or non-marketed product one month prior to Visit 1 and during the trial.

- Any concurrent illness that may render a participant ineligible or limit compliance with study requirements.

- Previously enrolled in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
alpha1H, 7.4 mg/mL
Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Other:
placebo
Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Drug:
alpha1H, 37 mg/mL
Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
alpha1H, 74 mg/mL
Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)

Locations

Country Name City State
Czechia Motol University Hospital Prague

Sponsors (1)

Lead Sponsor Collaborator
Hamlet Pharma AB

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety as Adverse Events Profile Incidence of adverse events and classification in terms of severity, causality and outcome From signing of informed consent (Day 1) and until 30 days after the last dose (Day 52).
Primary Efficacy as Cell Shedding Change in cell shedding into urine (number of epithelial cells per mL of urine). Days 1 to 22
Primary Change from baseline in characteristics of papillary tumors The bladder tumors will be characterised by in vivo imaging during examination by cystoscopy. Prior to treatment (Baseline) and on Day 30, in connection with scheduled surgery.
See also
  Status Clinical Trial Phase
Recruiting NCT04736394 - A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients Phase 3
Recruiting NCT05951179 - Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer Phase 2
Active, not recruiting NCT04943094 - Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
Not yet recruiting NCT06227065 - Precise Neoadjuvant Chemoresection of Low Grade NMIBC Phase 2
Completed NCT02969109 - Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
Completed NCT01458847 - Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer Phase 1
Recruiting NCT03914794 - A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors Phase 2
Recruiting NCT05126472 - Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment Phase 1
Recruiting NCT04644835 - Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer N/A
Recruiting NCT06126796 - Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Active, not recruiting NCT04100733 - Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor N/A
Recruiting NCT05085990 - Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer Phase 1
Terminated NCT01310803 - Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder Phase 3
Completed NCT03081858 - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Phase 1/Phase 2
Completed NCT04498702 - Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy Phase 2
Recruiting NCT05337397 - Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
Active, not recruiting NCT04490993 - Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients Phase 3
Recruiting NCT04859751 - Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer Phase 3
Recruiting NCT05672615 - Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Not yet recruiting NCT06245603 - A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer N/A